Cabaletta Bio (NASDAQ:CABA) Insider Steve Gavel Purchases 22,170 Shares

Cabaletta Bio, Inc. (NASDAQ:CABA) insider Steve Gavel acquired 22,170 shares of the firm’s stock in a transaction that occurred on Wednesday, January 21st. The stock was purchased at an average cost of $2.27 per share, with a total value of $50,325.90. Following the purchase, the insider directly owned 22,170 shares in the company, valued at approximately $50,325.90. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Cabaletta Bio Stock Up 6.8%

Shares of NASDAQ:CABA opened at $2.34 on Thursday. The company’s fifty day moving average is $2.29 and its two-hundred day moving average is $2.11. The company has a market cap of $225.25 million, a P/E ratio of -0.92 and a beta of 3.25. Cabaletta Bio, Inc. has a 12-month low of $0.99 and a 12-month high of $3.67.

Cabaletta Bio (NASDAQ:CABA) last issued its earnings results on Monday, November 10th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.05. Equities research analysts anticipate that Cabaletta Bio, Inc. will post -2.34 earnings per share for the current year.

Analyst Ratings Changes

CABA has been the subject of a number of research analyst reports. Jefferies Financial Group initiated coverage on shares of Cabaletta Bio in a research report on Friday, October 10th. They issued a “buy” rating and a $14.00 price target for the company. Cantor Fitzgerald upped their price objective on shares of Cabaletta Bio from $15.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Cabaletta Bio in a research note on Wednesday, October 8th. Finally, HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Cabaletta Bio in a report on Friday, October 10th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Cabaletta Bio currently has a consensus rating of “Moderate Buy” and an average target price of $16.25.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Bain Capital Life Sciences Investors LLC raised its holdings in shares of Cabaletta Bio by 250.5% during the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 9,677,125 shares of the company’s stock valued at $14,709,000 after purchasing an additional 6,916,237 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its position in Cabaletta Bio by 142.9% during the second quarter. Adage Capital Partners GP L.L.C. now owns 8,829,758 shares of the company’s stock worth $13,421,000 after buying an additional 5,195,285 shares during the last quarter. Jennison Associates LLC raised its holdings in Cabaletta Bio by 147.4% during the second quarter. Jennison Associates LLC now owns 6,020,167 shares of the company’s stock valued at $9,151,000 after buying an additional 3,586,439 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Cabaletta Bio by 21.4% in the third quarter. Vanguard Group Inc. now owns 4,190,759 shares of the company’s stock worth $9,806,000 after buying an additional 740,032 shares during the last quarter. Finally, Woodline Partners LP boosted its stake in shares of Cabaletta Bio by 75.2% during the 3rd quarter. Woodline Partners LP now owns 2,135,348 shares of the company’s stock worth $4,997,000 after acquiring an additional 916,884 shares in the last quarter.

Key Headlines Impacting Cabaletta Bio

Here are the key news stories impacting Cabaletta Bio this week:

• Positive Sentiment: CEO Steven Nichtberger purchased 45,000 shares at an average $2.24/share (≈$100,800), increasing his stake to ~1.03M shares — a meaningful insider buy from the company’s top executive. SEC filing
• Positive Sentiment: Director Mark Simon acquired 11,061 shares at ~$2.28/share (~$25.2K), an 8.12% increase in his holding to ~147K shares. SEC filing
• Positive Sentiment: General Counsel Michael Gerard bought 6,600 shares at $2.27/share (~$15K), initiating a new disclosed holding. SEC filing
• Positive Sentiment: Other insiders (director Shawn Tomasello, insider Steve Gavel, Gwendolyn Binder, David J. Chang) executed purchases ranging ~8.8K–22.7K shares at ~$2.19–$2.27 each, many representing large % increases in their positions — broad insider participation suggests aligned bullish views across management and the board. SEC filings
• Positive Sentiment: Report: Cabaletta is accelerating its autoimmune CAR‑T program and is targeting a 2027 FDA filing — a multi‑year development path but one that, if achieved, would be value‑creating. Cabaletta targets 2027 FDA filing as autoimmune CAR-T push accelerates

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.